| Mitoxantrone in the treatment of relapsed and refractory acute leukemia. | |
| | |
MedLine Citation:
|
PMID: 6385265 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Eleven academic institutions were selected to study mitoxantrone administered on a schedule of 10 mg/m2/d for five days initially and later at 12 mg/m2/d for five days, each given as a 30 minute intravenous (IV) infusion each day. Patients with acute or chronic leukemia were stratified by leukemic type and clinical status and included one group of patients considered to be in relapse after complete remission from previous chemotherapy and another group of patients considered refractory to standard induction and/or salvage chemotherapy. During the initial treatment schedule, complete remissions were obtained in two of seven patients with acute nonlymphoblastic leukemia, in one of three patients with acute lymphoblastic leukemia, but in none of the patients with chronic granulocytic leukemia in blast crisis. The durations of remission for these three patients were 22, 57, and 78 days, respectively. An increase in mitoxantrone dose to 12 mg/m2/d produced complete remissions in 8 of 19 evaluable patients with acute nonlymphoblastic leukemia, in one of ten patients with refractory acute nonlymphoblastic leukemia, and in one of four patients with chronic granulocytic leukemia in blast crisis. Each of these patients required only a single course of mitoxantrone to achieve remission; the median time to remission was 37 days (range 18 to 64 days). Remission duration ranged from 35 days (chronic granulocytic leukemia) to 186 days, with the median duration for those patients with acute nonlymphoblastic leukemia achieving remission being 135 days. Of the six patients with acute lymphoblastic leukemia, none achieved remission at the higher dose level. Drug-related gastrointestinal toxicity included mucositis (25%), diarrhea (21%), and nausea and vomiting (61%). Systemic infection (nonfatal) was experienced by 21% of patients and alopecia by 17%. Other side effects that occurred occasionally were hepatic dysfunction, decreased renal function, confusion, lethargy, anxiety, and fever. Possible drug-related phlebitis developed in one patient, and a single episode of minor epistaxis was reported in another. Cardiovascular toxicity was low. At a mitoxantrone dose of 10 mg/m2/d for five days, one patient developed hypotension, and one episode of congestive heart failure was reported in another. At the higher dose of 12 mg/m2/d, no drug-related hypotension, congestive heart failure, tachycardia, or chest pain were reported. These data indicate that mitoxantrone is a promising single drug for the treatment of acute nonlymphoblastic leukemia and possibly for acute lymphoblastic leukemia. |
| | |
Authors:
|
J O Moore; G A Olsen |
Related Documents
:
|
15036945 - Divergent clinical outcome in two cml patients who discontinued imatinib therapy after ... 16493615 - Role of cyp2d6, cyp1a1, cyp2e1, gstt1, and gstm1 genes in the susceptibility to acute l... 3546615 - Acute lymphoblastic leukemia with chromosomal 5;14 translocation and hypereosinophilia:... 11578365 - Intraperitoneal interferon-alpha-2b for patients with no macroscopic disease following ... 18098275 - Tremor dominant parkinsonism: clinical description and lrrk2 mutation screening. 19560085 - The esophageal effects of cryoenergy during cryoablation for atrial fibrillation. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Seminars in oncology Volume: 11 ISSN: 0093-7754 ISO Abbreviation: Semin. Oncol. Publication Date: 1984 Sep |
Date Detail:
|
Created Date: 1984-11-01 Completed Date: 1984-11-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0420432 Medline TA: Semin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 41-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adult Aged Anthraquinones / administration & dosage, therapeutic use*, toxicity Antineoplastic Agents / therapeutic use* Clinical Trials as Topic Drug Administration Schedule Female Follow-Up Studies Heart / drug effects Humans Infusions, Parenteral Leukemia / drug therapy* Leukemia, Lymphoid / drug therapy Leukemia, Myeloid / drug therapy Male Middle Aged Mitoxantrone |
| Chemical | |
Reg. No./Substance:
|
0/Anthraquinones; 0/Antineoplastic Agents; 65271-80-9/Mitoxantrone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leu...
Next Document: Clinical safety and tolerance of mitoxantrone.